As part of ARLG’s Scientific Agenda to prioritize clinical research focused on novel diagnostics, a new partnership with Biomeme, an innovative biotechnology company, centers on studying a host response test to quickly differentiate between bacterial and viral infections. The goal of the Rapid Diagnostic in Categorizing Acute Lung Infections, (RADICAL 510k) Study is to evaluate the performance of Biomeme’s new assay, which looks for host gene expression in blood to determine whether a patient has a bacterial infection, viral infection, or neither.
Giving physicians the power to quickly and accurately discover the cause of an infection helps them to develop the most effective treatment plans for their patients. By avoiding inappropriate use of antibiotics in settings where they won’t be therapeutic, physicians can also improve their antibiotic stewardship.
ARLG Principal Investigators Gayani Tillekeratne, MD and Thomas Holland, MD are leading the RADICAL 510k Study.
“This is a great opportunity for some of the world’s leading researchers in this space to work together to evaluate new products with the potential to improve antibiotic stewardship,” said Holland. “We are working with the FDA on the study design and are very appreciative of their input thus far.”
By collaborating together, both Biomeme and ARLG hope to combat the global threat of antimicrobial resistance by adding to physicians’ diagnostic toolset.